Workflow
春立医疗(01858.HK)7月24日收盘上涨13.04%,成交6465.63万港元
Sou Hu Cai Jing·2025-07-24 08:30

Core Viewpoint - Spring Medical has shown significant stock performance, with a year-to-date increase of 73.18%, outperforming the Hang Seng Index by 27.31% [2] Financial Performance - As of March 31, 2025, Spring Medical reported total revenue of 230 million yuan, a year-on-year increase of 3.6% - The net profit attributable to shareholders was 58.071 million yuan, reflecting a growth of 5.2% - The gross profit margin stood at 66.69%, while the debt-to-asset ratio was 17.11% [2] Market Position and Valuation - Currently, there are no institutional investment ratings for Spring Medical - The company's price-to-earnings (P/E) ratio is 41.21, ranking 45th in the healthcare equipment and services industry, which has an average P/E ratio of -1.39 and a median of 1.36 [3] Company Overview - Founded in 1998, Spring Medical focuses on high-end medical device development, offering a full range of orthopedic products including joint, spine, sports medicine, and trauma products - The company has 124 medical device registrations and continues to expand its product line to meet diverse market needs [3][4] Research and Development - Spring Medical boasts a multidisciplinary team with over 20 years of industry experience, including experts in mechanical design, materials science, biomechanics, and clinical medicine - The company has received multiple qualifications, including being recognized as a national high-tech enterprise and a champion enterprise in manufacturing [4] Innovation and Market Strategy - As a leading player in China's orthopedic industry, Spring Medical has filled domestic market gaps with innovative products, enhancing its core competitiveness and industry recognition - The company aims to solve key technical challenges in the industry and promote independent innovation in the joint field [5]